Evidence map›Paper›PMID 37604982›Full record

ReviewNature reviews. Urology2024

Bioinformatics in urology - molecular characterization of pathophysiology and response to treatment.

Ali Hashemi Gheinani, Jina Kim, Sungyong You, Rosalyn M Adam

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali Hashemi GheinaniDepartment of Urology, Boston Children's Hospital, Boston, MA, USA.ORCID 0000-0002-9625-6259
Jina KimDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sungyong YouDepartment of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0003-3513-1783
Rosalyn M AdamDepartment of Urology, Boston Children's Hospital, Boston, MA, USA. rosalyn.adam@childrens.harvard.edu.ORCID 0000-0002-0943-6236

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The application of bioinformatics has revolutionized the practice of medicine in the past 20 years. From early studies that uncovered subtypes of cancer to broad efforts spearheaded by the Cancer Genome Atlas initiative, the use of bioinformatics strategies to analyse high-dimensional data has provided unprecedented insights into the molecular basis of disease. In addition to the identification of disease subtypes - which enables risk stratification - informatics analysis has facilitated the identification of novel risk factors and drivers of disease, biomarkers of progression and treatment response, as well as possibilities for drug repurposing or repositioning; moreover, bioinformatics has guided research towards precision and personalized medicine. Implementation of specific computational approaches such as artificial intelligence, machine learning and molecular subtyping has yet to become widespread in urology clinical practice for reasons of cost, disruption of clinical workflow and need for prospective validation of informatics approaches in independent patient cohorts. Solving these challenges might accelerate routine integration of bioinformatics into clinical settings.

Indexed as

NeoplasmsUrologyArtificial IntelligenceComputational BiologyHumansPrecision Medicine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.